Meriwether Wealth & Planning LLC Takes $66,000 Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Meriwether Wealth & Planning LLC bought a new stake in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 21,640 shares of the company’s stock, valued at approximately $66,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Erste Asset Management GmbH acquired a new stake in shares of Zentalis Pharmaceuticals in the 3rd quarter valued at $37,000. Paloma Partners Management Co acquired a new stake in shares of Zentalis Pharmaceuticals during the third quarter worth $37,000. Aigen Investment Management LP acquired a new stake in shares of Zentalis Pharmaceuticals during the third quarter worth $41,000. Capstone Investment Advisors LLC acquired a new stake in shares of Zentalis Pharmaceuticals during the third quarter worth $48,000. Finally, Quarry LP acquired a new stake in shares of Zentalis Pharmaceuticals during the third quarter worth $55,000.

Insider Activity

In other news, insider Ingmar Bruns purchased 20,000 shares of the business’s stock in a transaction dated Thursday, February 6th. The shares were bought at an average cost of $2.28 per share, for a total transaction of $45,600.00. Following the completion of the acquisition, the insider now directly owns 36,629 shares in the company, valued at approximately $83,514.12. This trade represents a 120.27 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jan Skvarka purchased 60,000 shares of the business’s stock in a transaction dated Friday, January 31st. The stock was purchased at an average price of $1.72 per share, for a total transaction of $103,200.00. Following the completion of the acquisition, the director now owns 149,551 shares of the company’s stock, valued at approximately $257,227.72. This represents a 67.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 3.60% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. Guggenheim decreased their price objective on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a research note on Friday, November 15th. UBS Group decreased their price objective on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. Wedbush reaffirmed a “neutral” rating and set a $4.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Friday, January 24th. Wells Fargo & Company decreased their price objective on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating for the company in a research note on Thursday, January 30th. Finally, HC Wainwright decreased their target price on Zentalis Pharmaceuticals from $20.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday, January 29th. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $8.24.

Zentalis Pharmaceuticals Trading Down 5.7 %

NASDAQ:ZNTL opened at $1.82 on Monday. Zentalis Pharmaceuticals, Inc. has a 1 year low of $1.61 and a 1 year high of $16.27. The stock has a market cap of $129.70 million, a price-to-earnings ratio of -0.73 and a beta of 1.75. The stock has a 50-day moving average price of $2.33 and a two-hundred day moving average price of $2.99.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.